Cincinnati, OHNCT06234397Now EnrollingIRB Ready

Advanced or Metastatic Solid Tumors Clinical Trial in Cincinnati, OH

Access cutting-edge advanced or metastatic solid tumors treatment through this clinical trial at a research site in Cincinnati. Study-provided care at no cost to qualified participants.

Sponsored by Hanmi Pharmaceutical Company Limited

Quick Self-Assessment

See if you qualify for this Cincinnati location

Preparing your pre-screening questions…

Expert Care in Cincinnati

Access advanced or metastatic solid tumors specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related advanced or metastatic solid tumors treatment provided free

Apply for This Cincinnati Location

Check if you qualify for this advanced or metastatic solid tumors clinical trial in Cincinnati, OH

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Cincinnati

    Convenient for OH residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Cincinnati site if eligible
  4. 4Begin participation

About This Advanced or Metastatic Solid Tumors Study in Cincinnati

This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of BH3120, as a single agent and in combination with pembrolizumab, to assess safety, tolerability, MTD, RP2D, PK, and efficacy in patients with advanced or metastatic solid tumors. Dose-Escalation part is planned to establish the MTD or RD for Dose-Expansion part, while Dose-Expansion part is designed to assess potential efficacy of BH3120, as a single agent and in combination with pembrolizumab, when administered at the RD to subjects in indication-specific expansion cohorts.

Sponsor: Hanmi Pharmaceutical Company Limited

Who Can Participate

Inclusion Criteria

Have a Histologically or cytologically confirmed non-CNS solid tumor that is metastatic or unresectable and for whom there is no available standard therapy.
PD-L1 positive expression (Tumor Proportion Score ≥1% or Combined Positive Score ≥1).
Have at least one lesion, not previously irradiated that can be accurately measured per RECIST version 1.1.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Age of 18 years or older (or country's legal age of majority if the legal age was \>18 years)
Adequate Hematologic and liver function. Key

Exclusion Criteria

Has received prior therapy with an anti-4-1BB(CD137) agent.
Known active CNS metastases and/or carcinomatous meningitis.
Known additional malignancy that is progressing or has required active treatment.
History of chronic liver disease or evidence of hepatic cirrhosis.
History of severe toxicities associated with a prior immunotherapy.
Has ongoing or suspected autoimmune disease.
Known active and clinically significant bacterial, fungal or viral infection including known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, immunocompromised patients.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Cincinnati?

Yes, this clinical trial (NCT06234397) has an active research site in Cincinnati, OH that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced or Metastatic Solid Tumors Treatment Options in Cincinnati, OH

If you're searching for advanced or metastatic solid tumors treatment options in Cincinnati, OH, this clinical trial (NCT06234397) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Cincinnati research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced or metastatic solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced or metastatic solid tumors clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Cincinnati, OH

See all advanced solid tumors clinical trials recruiting in Cincinnati — not just this study.

Browse Advanced Solid Tumors Trials in Cincinnati →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAlzheimers Disease TrialsEssential Tremor TrialsAnkylosing Spondylitis TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Cincinnati?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Cincinnati, OH